Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has presented the latest two clinical trials (Study 202 and Study 006) data on its in-house discovered oral BACE (beta amyloid cleaving enzyme ) inhibitor elenbecestat (development code: E2609) at the 9th Clinical Trials on Alzheimer’s Disease (CTAD 2016) held from December 8 to 10 in San Diego, the United States.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa®) and rufinamide (product name: Inovelon®, U.S. product name: BANZEL®) will be presented at the 70th American Epilepsy Society (AES) Annual Meeting to be held from December 2 to 6 in Houston in the United States.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its in-house developed anticancer agent Halaven® (eribulin mesylate, “eribulin”) has been recommended by the U.K. National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease (prior therapy may have included an anthracycline or a taxane, and capecitabine) in NICE’s Final Appraisal Determination (FAD). Eribulin is the first breast cancer treatment to be recommended by NICE since 2007. 

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it will launch its first food with function claims Chocola BB® Rich Ceramide (Notification number: B60) in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. The product is Japan’s first drink that is a type of food with function claims containing glucosylceramide derived from rice.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.